DCALBSEDishman Carbogen Amcis LtdHighPositive
Announced Tue, 5 May · 19:34 IST

Pls. find enclosed herewith the Press Release regarding the Company''s wholly owned subsidiary.

Business Updates View source PDF

DCAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.7%1-day move
₹186.16
prior close
₹191.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.0-1.2-1.3-1.4+2.7+0.3-1.2-5.1-5.1+4.4+6.1-1.1+5.3
Up moveDown movePending
AI summary

Dishman Carbogen Amcis Ltd's wholly-owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has successfully cleared an unannounced Good Manufacturing Practice inspection by China's National Medical Products Administration. The inspection was conducted on April 14, 2026, and covered API manufacturing operations and the site's Quality System. No observations or issues were identified, which is a clean outcome. The Shanghai facility supports API manufacturing and process development within CARBOGEN AMCIS' global network. Company management called this a significant achievement that validates their global quality culture and confirms the site as a reliable partner for customers worldwide.

Likely market impact

This is a positive regulatory validation for the subsidiary's operations, strengthening confidence in the company's quality standards. Passing an unannounced inspection with no observations supports business continuity in China and global pharmaceutical markets, which is beneficial for the parent company's outsourcing partnerships.